Booster Dose of sIPV Co-administered With MMR and HepA-I.

Exclusion Criteria

• •(1) a history of vaccination with a polio-containing vaccine component in addition to three sIPV primary doses, according to the vaccination certificate;
• •(2) have received a second dose of MMR vaccine or a vaccine containing a vaccine for measles, mumps or rubella, or hepatitis A vaccine (inactivated or attenuated), according to the vaccination certificate;
• •(3) previous history of polio or measles or mumps or rubella or hepatitis A;
• •(4) known severe allergy to the vaccine or vaccine components, such as urticaria, dyspnea, angioedema;
• •(5) severe congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
• •(6) with autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, asplenia, functional asplenia, and HIV infection);
• •(7) abnormal coagulation function (such as coagulation factor deficiency, platelet abnormality), or obvious bleeding, hematoma, or ecchymosis after previous intramuscular injection or venipuncture;
• •(8) have/have had a serious neurological disease (e.g., encephalopathy, epilepsy, convulsions \[other than febrile convulsions\]) or psychosis, a family history of neurological disease or psychosis;
• •(9) receiving immunosuppressive or other immunomodulatory therapy, cytotoxic therapy within the past 6 months, or planning to receive such treatment during the trial;
• •(10) have received an immune globulin or other blood products within the past 6 months or plan to receive such treatment during the trial;
• •(11) receipt of other investigational vaccines within 30 days before vaccination with the investigational vaccines;
• •(12) receipt of live attenuated vaccine within 28 days before vaccination with the investigational vaccine;
• •(13) receipt of subunit or inactivated vaccine within 7 days before vaccination with the investigational vaccine;
• •(14) acute diseases or acute episodes of chronic diseases within the past 7 days;
• •(15) Axillary temperature \>37.0℃ if fever occurred before vaccination;
• •(16) which are unsuitable for participation in the clinical trial as judged by the investigators.